All In Biotech

Drug Trial Radar · NCT02207491

Double-masked Study of AR-13324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

A Double-masked, Randomized, Multi-center, Active-controlled, Parallel, 3-month Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-13324 Ophthalmic Solution, 0.02% Compared to Timolol Maleate Ophthalmic Solution, 0.5% in Patients With Elevated Intraocular Pressure

Last checked: Nov 20, 2026Latest source record: Apr 13, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 411 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

411

Actual

Start

Jul 2014

Primary completion

Mar 2015

Study completion Mar 2015

Sponsor

Lead sponsor
Aerie PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Aug 4, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the ocular hypotensive efficacy and ocular and systemic safety of AR-13324 Ophthalmic Solution, 0.02% compared to the active comparator Timolol maleate Ophthalmic Solution, 0.5%

Conditions

  • Ocular Hypertension
  • Open-angle Glaucoma

Interventions

  • Timolol maleate Ophthalmic Solution 0.5% BIDDrug

    1 drop BID, AM/PM, OU

  • AR-13324 Ophthalmic Solution 0.02%Drug

    1 drop once daily (QD), PM, OU

  • PlaceboOther

    1 drop QD, AM, OU

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Intraocular Pressure (IOP)Time frame: 3 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Aerie Pharmaceuticals

    Bedminster, New Jersey

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.